Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16627759 
Rocnik JL, et al. (2006) Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108, 1339-45 16627759
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y589-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y589‑p, FLT3 (mouse): Y590‑p, FLT3 iso3 (mouse): Y590‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  32D (myeloid) [FLT3 (human)], BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  FLT3 is either WT or consitutively active due to internal tandem duplications (ITD) as observed in AML cells. With and without point mutations.
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Effect of modification (process):  cell growth, altered
 Comments:  The double mutation Y589/591F has a slower growth rate (this is in the ligand-independent, constitutive active allele).; While none of the single mutations affected STAT-5 phosphotyrosine levels, 3 double mutations did: Y591/726F, Y591/955F, Y589/591F (all three pairs have Y591F in common).

Y591-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y591‑p, FLT3 (mouse): Y592‑p, FLT3 iso3 (mouse): Y592‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  32D (myeloid) [FLT3 (human)], BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  FLT3 is either WT or consitutively active due to internal tandem duplications (ITD) as observed in AML cells. With and without point mutations.
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE FLT3 (human)
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Effect of modification (process):  cell growth, altered
 Comments:  The double mutation Y589/591F has a slower growth rate (this is in the ligand-independent, constitutive active allele).; While none of the single mutations affected STAT-5 phosphotyrosine levels, 3 double mutations did: Y591/726F, Y591/955F, Y589/591F (all three pairs have Y591F in common).

Y726-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y726‑p, FLT3 (mouse): Y727‑p, FLT3 iso3 (mouse): Y727‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  32D (myeloid) [FLT3 (human)], BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  FLT3 is either WT or consitutively active due to internal tandem duplications (ITD) as observed in AML cells. With and without point mutations.
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE FLT3 (human)
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Comments:  While none of the single mutations affected STAT-5 phosphotyrosine levels, 3 double mutations did: Y591/726F, Y591/955F, Y589/591F (all three pairs have Y591F in common).

Y842-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y842‑p, FLT3 (mouse): Y845‑p, FLT3 iso3 (mouse): Y845‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE FLT3 (human)

Y955-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y955‑p, FLT3 (mouse): I958‑p, FLT3 iso3 (mouse): Y958‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  32D (myeloid) [FLT3 (human)], BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  FLT3 is either WT or consitutively active due to internal tandem duplications (ITD) as observed in AML cells. With and without point mutations.
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE FLT3 (human)
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Comments:  While none of the single mutations affected STAT-5 phosphotyrosine levels, 3 double mutations did: Y591/726F, Y591/955F, Y589/591F (all three pairs have Y591F in common).

Y969-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y969‑p, FLT3 (mouse): Q971‑p, FLT3 iso3 (mouse): Y972‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  32D (myeloid) [FLT3 (human)], BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Comments:  FLT3 is either WT or consitutively active due to internal tandem duplications (ITD) as observed in AML cells. With and without point mutations.
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE FLT3 (human)

T203-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase in WT FLT3 receptor (lost in multiple Y->F allele)

Y205-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase in WT FLT3 receptor (lost in multiple Y->F allele)

T183-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase in WT FLT3 receptor (lost in multiple Y->F allele)

Y185-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor') [FLT3 (human)]
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase in WT FLT3 receptor (lost in multiple Y->F allele)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.